Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer

Authors

Institutions

Publication Details

Journal
iScience
Published
2026-04-15
DOI
https://doi.org/10.1016/j.isci.2026.115722
Primary Topic
IL-33, ST2, and ILC Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer

Yingpu Li, Lanning Jia, Zehao Li, Ziyi Li et al.
iScience
IL-33, ST2, and ILC Pathways
article

Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer

Yingpu Li, Lanning Jia, Zehao Li, Ziyi Li, Shuxian Yang, Yuan Qi, Sifan Zhang
article en

Abstract

No abstract available for this paper.
iScienceVol. 29(5)
Jiamusi University (CN), Harbin Medical University (CN), Tianjin Medical University General Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), First Affiliated Hospital of Harbin Medical University (CN), Heilongjiang University (CN)
Natural Science Foundation of Heilongjiang Province
Good health and well-being
Openalex Percentile: Top 27%
IL-33, ST2, and ILC Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.